nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma
详细信息 查看全文
- 作者：Douglas Adkins ; MDa ; b ; dadkins@dom.wustl.edu" class="auth_mail" title="E-mail the corresponding author ; Jessica Ley ; BSb ; Loren Michel ; MDa ; b ; Tanya M. Wildes ; MD ; MSCIa ; b ; Wade Thorstad ; MDa ; c ; Hiram A. Gay ; MDa ; c ; Mackenzie Daly ; MDa ; c ; Jason Rich ; MDa ; d ; Randal Paniello ; MDa ; d ; Ravindra Uppaluri ; MDa ; d ; Ryan Jackson ; MDa ; d ; Kathryn Trinkaus ; PhDa ; e ; Brian Nussenbaum ; MDa ; d
- 关键词：Head and neck cancer ; nab-Paclitaxel ; Cisplatin ; 5-Fluorouracil ; Induction ; Chemotherapy
- 刊名：Oral Oncology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：61
- 期：Complete
- 页码：1-7
- 全文大小：601 K
文摘
Phase II trial: nab-paclitaxel, cisplatin and 5-FU (APF) followed by CRT.
Two-year DSS (97%) and OS (93%) were excellent.
Relapse rate was very low (3%).